Phase III Immunogenicity and Safety Clinical Trial of Convidecia Vaccine Completed in Russia
The Convidecia COVID-19 vaccine has demonstrated high immunogenicity and safety in the local Phase III clinical trial in Russia. Data was presented in the final study report sent by Petrovax to Russia’s Ministry of Health in early August. According to the study, one dose of the vaccine provides a pronounced immune response, with favorable tolerability and a high safety profile.
Independent International Committee Confirms that the Ad5-nCoV (Convidecia) Vaccine Complies with Previously Specified Safety and Efficacy Criteria
